Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Oct 13 · below the Ichimoku cloud · RSI 29 (oversold) · MACD below its signal · at its 52-week low
None of the 29 investors followed here reported a position in THRM.V in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a THRM.V trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for THRM.V.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 18.2 | -7.7 | 16.7 | -21.4 | 0.0 | -9.1 | 0.0 | -10.0 | 0.0 | -22.2 | −36.4% | ||
| 2025 | 14.3 | -12.5 | -14.3 | -33.3 | 0.0 | -50.0 | -12.5 | -7.1 | 69.2 | -31.8 | -33.3 | 10.0 | −80.4% |
| 2024 | 0.0 | -20.0 | 0.0 | -50.0 | 50.0 | 33.3 | 25.0 | 180.0 | -14.3 | -41.7 | -21.4 | 27.3 | +40.0% |
| 2023 | 0.0 | 58.3 | -26.3 | 0.0 | -14.3 | -25.0 | -11.1 | 0.0 | 0.0 | -12.5 | -42.9 | 25.0 | −58.3% |
| 2022 | -11.0 | -33.6 | -13.4 | -14.3 | -16.7 | -13.3 | 15.4 | -16.7 | -48.0 | 38.5 | 16.7 | -42.9 | −85.4% |
| 2021 | 141.9 | -31.7 | 46.5 | -14.4 | -19.1 | -2.8 | 17.1 | -12.2 | 8.3 | -1.3 | -9.1 | 17.1 | +90.7% |
| 2020 | -33.3 | 0.0 | 0.0 | 50.0 | 66.7 | 0.0 | 640.0 | -16.2 | -16.1 | -15.4 | -31.8 | 186.7 | +1333.3% |
| 2019 | 0.0 | 20.0 | -16.7 | 40.0 | 0.0 | -14.3 | -16.7 | -40.0 | 33.3 | -25.0 | 33.3 | -25.0 | −40.0% |
| 2018 | 6.3 | -17.6 | -28.6 | -20.0 | 0.0 | -12.5 | -14.3 | 0.0 | 50.0 | -33.3 | -16.7 | 0.0 | −68.7% |
| 2017 | 0.0 | 260.0 | -11.1 | -12.5 | -21.4 | 9.1 | 33.3 | 12.5 | 55.6 | -50.0 | -14.3 | 33.3 | +220.0% |
| 2016 | 0.0 | -50.0 | 0.0 | 0.0 | 0.0 | 100.0 | -50.0 | 100.0 | 0.0 | -50.0 | 300.0 | 25.0 | +150.0% |
| 2015 | -28.6 | -20.0 | -50.0 | 50.0 | -33.3 | -50.0 | 0.0 | 0.0 | 100.0 | 200.0 | -33.3 | -50.0 | −71.4% |
| 2014 | 0.0 | 0.0 | 0.0 | -33.3 | -50.0 | 0.0 | 100.0 | 0.0 | 0.0 | -50.0 | 400.0 | 40.0 | +133.3% |
| 2013 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% |
| 2012 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% |
| 2011 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% |
| 2010 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0% |
| 2009 | 0.0 | 50.0 | 0.0 | 33.3 | 150.0 | -70.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | +50.0% |
| 2008 | -16.7 | 26.7 | -21.1 | -33.3 | -20.0 | 0.0 | -12.5 | 42.9 | -40.0 | -66.7 | 50.0 | -33.3 | −88.9% |
| 2007 | 8.7 | 36.0 | -41.2 | 7.5 | -11.6 | -31.6 | -19.2 | 23.8 | -23.1 | 50.0 | -33.3 | -10.0 | −60.9% |
No analyst coverage for this instrument.
Therma Bright Inc. acquires, develops, manufactures, and markets proprietary healthcare and medical devices focused on respiratory diseases, vascular health, and consumer medical devices for consumer and institutional marketplace. Its products include AcuVid, an antigen and antibody rapid screening test for COVID-19; InterceptCS, a cold sore prevention system, which provides controlled topical heat without the risk of burning the skin; Benepod, a hot and cold contrast therapy device for pain relief without pain relieving medication; Venowave, a medical compression pump designed to treat and alleviate the symptoms associated with poor circulation; and TherOZap, a thermal therapy insect device that reduces the inflammatory response, as well as relieves the symptoms of pain, itching, and inflammation associated with insect bites and stings. The company also offers Inretio, a medical device for ischemic stroke treatment; Digital Cough Test (DCT), an app that uses artificial intelligence to detect multiple respiratory diseases; and inhaled statin therapy for the treatment of COVID-19 pneumonia and acute respiratory distress syndrome in hospitalized patients. It serves consumers and medical professionals. The company was formerly known as The Jenex Corporation and changed its name to Therma Bright Inc. in February 2018. Therma Bright Inc. was incorporated in 2001 and is based in Toronto, Canada.
No recent headlines.